Compare iShares MSCI Malaysia ETF (EWM) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Humana Inc — how do they compare? iShares MSCI Malaysia ETF trades at $26.66 (market cap $256.41M), while Humana Inc trades at $430.56 (market cap $46.49B). The key difference: Humana Inc is far larger — about 181.3× iShares MSCI Malaysia ETF's market cap, and Humana Inc pays a 0.91% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 66 Days and Humana Inc for 51 Days on average.
| EWM | HUM | |
|---|---|---|
Market Cap | $256.41M | $46.49B |
Volume | 111,962 | 2,567,704 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $409.85 |
52-Week Low | $25.33 | $163.67 |
Typical Hold Time | 66 Days | 51 Days |
Enterprise Value | — | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM is trading at $26.61, down 1.88% today, with a bearish technical signal from moving averages and neutral oscillators. Key financial ratios such as P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment. The stock lacks recent news coverage, creating uncertainty around current business developments and financial performance.
The outlook for EWM is cautious due to insufficient fundamental data and bearish technical indicators. Investment opportunities hinge on future earnings clarity, while risks include potential weak financials and negative market sentiment. Investors need updated SEC filings or analyst reports to gauge true valuation and growth prospects.
Humana (HUM) trades at $436.00, up 9.96% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has grown to $129.66 billion in 2025, though net income margin compressed to 0.88%. Analyst consensus is a buy with a $457.05 price target, and recent news highlights a Barclays upgrade and dividend declaration.
The outlook is positive given earnings momentum and institutional interest, but risks include margin pressure and regulatory scrutiny. Upside potential exists if the company maintains enrollment growth and cost controls, though investors should monitor Medicare Advantage plan changes and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
